Hansoh (3692) Announces NDA Acceptance for HS-10365 Capsules by NMPA

Bulletin Express

2025/10/23

Hansoh Pharmaceutical Group Company Limited (3692) announced that on October 23, 2025, the National Medical Products Administration of China accepted the New Drug Application (NDA) for HS-10365 capsules. HS-10365 is described as a potent and selective rearranged during transfection (RET) inhibitor, intended for adult patients with RET fusion-positive locally advanced or metastatic non-small cell lung cancer.

According to the announcement, this development represents a significant milestone in the Group’s efforts to advance treatments for RET fusion-positive NSCLC. The application’s acceptance marks an important regulatory step and reflects progress in the company’s innovative drug pipeline. The chairlady of the board, Zhong Huijuan, issued the announcement on behalf of Hansoh Pharmaceutical Group Company Limited on October 23, 2025.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1161900024"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1161900024\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1161900024?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-23 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161900024","market":"hk","top_or_hot":-1,"title":"Hansoh (3692) Announces NDA Acceptance for HS-10365 Capsules by NMPA","media":"Bulletin Express","content":"<p>Hansoh Pharmaceutical Group Company Limited (3692) announced that on October 23, 2025, the National Medical Products Administration of China accepted the New Drug Application (NDA) for HS-10365 capsules. HS-10365 is described as a potent and selective rearranged during transfection (RET) inhibitor, intended for adult patients with RET fusion-positive locally advanced or metastatic non-small cell lung cancer.</p>\n<p>According to the announcement, this development represents a significant milestone in the Group’s efforts to advance treatments for RET fusion-positive NSCLC. The application’s acceptance marks an important regulatory step and reflects progress in the company’s innovative drug pipeline. The chairlady of the board, Zhong Huijuan, issued the announcement on behalf of Hansoh Pharmaceutical Group Company Limited on October 23, 2025.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hansoh (3692) Announces NDA Acceptance for HS-10365 Capsules by NMPA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHansoh (3692) Announces NDA Acceptance for HS-10365 Capsules by NMPA\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2025-10-23 20:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Hansoh Pharmaceutical Group Company Limited (3692) announced that on October 23, 2025, the National Medical Products Administration of China accepted the New Drug Application (NDA) for HS-10365 capsules. HS-10365 is described as a potent and selective rearranged during transfection (RET) inhibitor, intended for adult patients with RET fusion-positive locally advanced or metastatic non-small cell lung cancer.</p>\n<p>According to the announcement, this development represents a significant milestone in the Group’s efforts to advance treatments for RET fusion-positive NSCLC. The application’s acceptance marks an important regulatory step and reflects progress in the company’s innovative drug pipeline. The chairlady of the board, Zhong Huijuan, issued the announcement on behalf of Hansoh Pharmaceutical Group Company Limited on October 23, 2025.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森製藥","start_time":0,"source_url":"","article_id":"1161900024","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161900024","pubTimestamp":1761220805,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hansoh Pharmaceutical Group Company Limited (3692) announced that on October 23, 2025, the National Medical Products Administration of China accepted the New Drug Application (NDA) for HS-10365...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03692":"翰森制药"},"translate_title":"豪森（3692）公布HS-10365胶囊获NMPA NDA受理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"Hansoh Pharmaceutical Group Company Limited (3692) announced that on October 23, 2025, the National Medical Products Administration of China accepted the New Drug Application (NDA) for HS-10365 capsules. HS-10365 is described as a potent and selective rearranged during transfection (RET) inhibitor, intended for adult patients with RET fusion-positive locally advanced or metastatic non-small cell lung cancer.\nAccording to the announcement, this development represents a significant milestone in the Group’s efforts to advance treatments for RET fusion-positive NSCLC. The application’s acceptance marks an important regulatory step and reflects progress in the company’s innovative drug pipeline. The chairlady of the board, Zhong Huijuan, issued the announcement on behalf of Hansoh Pharmaceutical Group Company Limited on October 23, 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}